Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02705638 · ClinicalTrials.gov registry record · Phase 1
Treatment of IgG4-Related Disease With Revlimid and Rituximab
A Phase 1 study of IgG4 Related Disease and Autoimmune Pancreatitis, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT02705638 is a Phase 1 study of IgG4 Related Disease and Autoimmune Pancreatitis that has completed, run by Mayo Clinic. The registered enrollment target is 6 participants, below the 91-participant average among 4 other IgG4 Related Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02705638, a Phase 1 study of IgG4 Related Disease and Autoimmune Pancreatitis, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Among persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who have persistent or recurrent disease despite standard therapies, does combination therapy with rituximab and revlimid cause a sustained disease remission?
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Lenalidomide
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-04 |
| Est. Completion | 2019-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02705638
The ClinicalTrials.gov registry entry for NCT02705638 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 4 other IgG4 Related Disease trials with a reported enrollment target (93% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with IgG4 Related Disease appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT02705638 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02705638 about?
NCT02705638 is a clinical study titled "Treatment of IgG4-Related Disease With Revlimid and Rituximab". Among persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who have persistent or recurrent disease despite standard therapies, does combination therapy with rituximab and revlimid cause a sustained disease remission?
What is the current status of trial NCT02705638?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-04. Estimated completion is 2019-04.
What conditions does trial NCT02705638 study?
This clinical trial studies the following conditions: IgG4 Related Disease, Autoimmune Pancreatitis, Immunoglobulin G Subclass 4 Related Disease, IgG4-related Sclerosing Cholangitis, Retroperitoneal Fibrosis.
What interventions are being tested in trial NCT02705638?
The interventions under investigation include: Rituximab (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT02705638?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02705638 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgG4 Related Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
RECRUITING · Phase 1
-
A Study of Efgartigimod in Patients With IgG4-Related Disease
RECRUITING · Phase 2
-
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.